Moxavidex Tablets Company :
Pharmed healthcare for utopia Pharmaceuticals.
Moxavidex Tablets Composition :
Each film coated tablet contains:
Active Ingredients:
Moxifloxacin hydrochloride 436.8 mg equivalent to 400mg
moxifloxacin .
Inactive Ingredients:
Lactose anhydrous – Avicel PH1 01- Povidon – Magnesium stearat
PEG 6000 – H.P.M.C-Titanium dioxide-Crosscarmellose sodium-Is
Moxavidex Tablets Pharmacological Action :
Moxavidex tablet has activity against a wide range of gram -positiv and gram-negative bacteria, its action results from inhibition of topoisomerase2 ( DNA gyrase ) and topisomerase 4 required for bacterial replication, transcription, repair, and recombination.
Moxavidex Tablets Pharmacokinetics :
Absorption: Moxifloxacin, given as an oral tablet, is well absorbed from the gastrointestinal tract. The absolute bioavailability of moxifloxacin is approximately 90 percent.
Distribution: Moxifloxacin is widely distributed throughout the body with tissue concentration often exceeding plasma concentration. Moxifloxacin has been detected in the saliva ,nasal and bronchial secretions, mucosa of the sinuses ,skin blister fluid, subcutaneous tissue, and skeletal muscle following oral administration of 400 m.
Metabolism: Moxifloxacin is metabolized via glucuronide and sulfate conjugation. The cytochrome p450 system is not involved in Moxifloxacin metabolism ,and is not affected by Moxifloxacin. It is eliminated primarily in the feces. Proximately 14% of an oral dose is excreted in the urine.
Excretion: Approximately 45% of an oral doses of Moxifloxacin is excreted uncharged drug (20% in the urine and 25%in faeces), tote of 96% ± 4% of an oral dose is excreted as either unchanged drug
or known metabolites.
Moxavidex Tablets Indications and Usage :
– Moxavidex tablets are indicated for the treatment of adults with infections caused by susceptible strains of the designated
Microorganism in the following condition:
– Acute Bacterial Sinusitis.
– Acute Bacterial Exacerbation of Chronic Bronchitis.
– Community Acquired Pneumonia.
– Uncomplicated Skin and Skin Structure Infections.
– Complicated Intra-abdominal Infections.
– Complicated Skin and Skin Structure Infections.
Moxavidex Tablets Dosage and Administration :
– The dosage of moxiftoxacin is one 400 mg tablet taken orally every 24 hours.
– Due to the designated pathogens Oral doses of moxiftoxacin should be administered at least 4 hours before or 8 hours after antacids containing, metal cations such as iron, and multivitamin preparations with zinc.
Moxavidex Tablets Contraindications :
Moxifloxacin contraindicated in persons with a history of hypersensitivity to moxifloxacin or any member of the quinolone class of antimicrobial agents.
Moxavidex Tablets Pregnancy & Lactation :
Moxiftoxacin is contraindicated during pregnancy category C
Moxavidex Tablets Adverse Reactions :
Rarely adverse reaction such as: Nausea, diarrhea, dizziness, headache, abdominal pain, vomiting, taste perversion, abnormal liver function test, and dyspepsia Post marketing experience: Exacerbation of myasthenia gravis.
Moxavidex Tablets Drug-Drug Interactions :
There was no clinically significant effect of moxifloxacin on theophyline, warfarin, digoxin. However, as with all other quinolones, iron and antacids significantly reduce the bioavailability of moxifloxacin.
Moxavidex Tablets Precautions :
– In general quinolones may cause nervousness, insomnia, anxiety or nightmares.
– Renal insufficiency: The pharmacokinetic parameters of moxifloxacin are not significantly altered by mild, moderate, or server renal impairment.
– The pharmacokinetics of moxifloxacin with moderate and severe hepatic insufficiency have not been, adequately studied due to the lack of clinical data, the use of moxifloxacin is not recommended with moderate and severe hepatic insufficiency.
– Moxifloxacin should be administered at least 4 hours before or 8 hours after antacids containing, metal cations such as iron, and multivitamin preparations with zinc. – QT Effects: Fluoroquinolones may prolong the QT interval in some patients. Moxifloxacin should be avoided in patients with a history of prolongation of the OT interval, patients with uncorrected electrolyte disorders (hypokalemia or hypomagnesemia), and patients receiving antiarrhythmic agents as quinidine.
– Exacerbation of myasthenia gravis: Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis. Postmarketing serious adverse events, including deaths and requirement for ventilator support, have been associated with fluoroquinolone use in persons with myasthenia gravis. Avoid fluoroquinolones in patients with known history of myasthenia gravis.
– Quinolones should not generally be used in patients aged less than 18 years, pregnant women, or breast-feeding mothers unless the benefits outweigh the risks.
Moxavidex Tablets Package :
Carton box contains 1 ( PVO I Aluminium) strip of 5 film coated tablets with insert leaflet.
Moxavidex Tablets Storage :
– Store at a temperature not exceeding 30·c in a dry place.
– Keep out of reach of children.
Moxavidex Tablets Informations for Patient :
– Keep this leaflet. You may need to read it again.
– If you have any further question, ask your doctor or pharmacist.
– This medicine has been prescribed for you.
– Do not pass it on to other.
– It may harm them, even if their symptoms are the same as yours.
– If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Moxavidex TabletsProduced by :
Pharmed Healthcare for Utopia Pharmaceuticals.